Denmark Sweden Norway Finland  Genzyme Danmark HomeKontaktGenzyme Corporate Home
Genzyme er ét af verdens førende bioteknologiske firmaer og vores mål, er at forbedre livet for patienter med alvorlige sygdomme. Læs mere her
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada (alemtuzumab) in Pivotal Studies

In approximately 70 percent of patients, disability scores improved or remained stable for an additional two years beyond the two-year pivotal multiple sclerosis studies.

Approximately 70 percent of patients treated with Lemtrada (alemtuzumab) did not receive a third course of treatment through the second year of the extension.

Cambridge, Mass. - September 11, 2014 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive interim results from the second year of the extension study of Lemtrada™ (alemtuzumab) for multiple sclerosis.
Mere >
Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio (teriflunomide) and Lemtrada (alemtuzumab) at ECTRIMS

CAMBRIDGE, Mass. – September 9, 2014 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that its multiple sclerosis pipeline, which includes a new generation of investigational treatments in early development, will be featured during the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) being held in Boston Sept. 10-13. The company will also present this week 26 oral and poster presentations from its MS franchise, including four-year results from the Lemtrada™ (alemtuzumab)extension study,12-year MRI data for Aubagio® (teriflunomide), and data from the Aubagio (teriflunomide) TOPIC study, which was recently published in The Lancet Neurology.
Mere >
FDA Approves Genzyme’s Cerdelga (eliglustat) Capsules - Only First-Line Oral Treatment for Adult Gaucher Disease Type 1

CAMBRIDGE, Mass.—Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced on August 19, 2014 that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only first-line oral therapy for certain adult Gaucher disease type 1 patients. A small number of adult patients who metabolize Cerdelga more quickly or at an undetermined rate, as detected by an established genetic laboratory test, will not be eligible for Cerdelga treatment. Cerdelga is expected to be available to patients within a month.
Mere >

genzyme i

Terms and Conditions Privacy Policy © 2008 Genzyme. All Rights Reserved. Webmaster